CliffBio
biologic

Herceptin Hylecta

trastuzumab and hyaluronidase-oysk

Loss of exclusivityFebruary 2031projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameHerceptin Hylecta
Active ingredienttrastuzumab and hyaluronidase-oysk
Strength600MG/5ML;10,000 UNITS/5ML (120MG/2,000UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalFebruary 2019
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Herceptin Hylecta patent cliff — loss of exclusivity February 2031 | CliffBio